Mercury Pharmaceuticals

24

Oct 2025

Bio-Rad’s iQ-Check Enterobacteriaceae Kit validated for detection of Enterobacteriaceae in infant formula and cereals

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation and approval of alternative methods for the microbiological analysis of food and beverages, has approved iQ-Check™ Enterobacteriaceae Kit for the real-time PCR detection of Enterobacteriaceae (EB) in infant formula, infant cereal with and without probiotics, and related ingredients.

READ MORE

24

Oct 2025

Bio-Rad’s iQ-Check Enterobacteriaceae Kit validated for detection of Enterobacteriaceae in infant formula and cereals

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation and approval of alternative methods for the microbiological analysis of food and beverages, has approved iQ-Check™ Enterobacteriaceae Kit for the real-time PCR detection of Enterobacteriaceae (EB) in infant formula, infant cereal with and without probiotics, and related ingredients.

READ MORE

24

Oct 2025

GOP talking point holds ACA is haunted by ‘phantom’ enrollees, but the devil’s in the data

The idea that Affordable Care Act marketplaces are riddled with fraud has become a major talking point among Republicans, as lawmakers in Congress argue about whether to extend the enhanced tax credits that are helping offset the cost of health care marketplace coverage for low- and middle-income people.

READ MORE

24

Oct 2025

Researchers identify nervous system components driving gastrointestinal cancer growth

Australian researchers have identified two nervous system components that drive tumor growth in gastrointestinal cancers, creating promising new avenues for treatment with existing approved therapies.

READ MORE

24

Oct 2025

Researchers uncover and inhibit a key cell death pathway in severe cutaneous adverse reactions

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, together with Prof. Takemasa Ozawa from the Department of Chemistry, School of Science, The University of Tokyo, and Dr. Yoichi Ogawa (Lecturer) from the Department of Dermatology, Faculty of Medicine, University of Yamanashi, has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

READ MORE

23

Oct 2025

Cannabis use now linked to increased risk of regular tobacco use in US youth

Teens and young adults who use cannabis are more likely to become regular tobacco users – even if they haven't previously tried tobacco – compared to similar people who do not use cannabis, suggests a US study published online in the journal Tobacco Control.

READ MORE

23

Oct 2025

Toxic compounds from heated e-cigarette fluids can damage lung cells

A study by University of California, Riverside, scientists has found that two toxic chemicals can form when the main ingredient in most e-cigarette fluids is heated, and that these compounds can harm human lung cells.

READ MORE

23

Oct 2025

Psilocybin and mindfulness offer new hope for depressive healthcare workers

Frontline healthcare workers struggling with depression after the COVID-19 pandemic experienced significant relief from a treatment combining psilocybin group therapy with mindfulness training, according to a new study from Huntsman Mental Health Institute at University of Utah Health.

READ MORE

23

Oct 2025

Breakthrough combo therapy lowers death risk in recurrent prostate cancer

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

READ MORE

23

Oct 2025

How COVID mRNA vaccines may make cancer treatments more effective

Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were linked to significantly longer survival in lung and melanoma cancer patients. The vaccines trigger a powerful type-I interferon response that primes tumors to become more responsive to immunotherapy.

READ MORE